Aneurysm, Brain Diseases, Cardiovascular Diseases, Intracranial Aneurysm
Conditions
Brief summary
A registration trial of the Intracranial Visualized stent in the treatment of wide-necked intracranial aneurysms
Interventions
Intracranial stent for wide-necked aneurysms
Sponsors
MicroPort NeuroTech Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* At the time of signing the informed consent form(ICF), the applicant shall be male or non-pregnant female, aged 18 to 80 years; * Target aneurysms was diagnosed as intracranial wide-necked saccular aneurysms(neck ≥4mm, or body-neck ratio \<2) by DSA/CTA/MRA； * The diameter of the parent vessel should be 2.0 to 4.5mm; * The target aneurysm should be suitable for stent-assisted coiling surgery and could be treated through one operation; * Subject or its legal representative should be able to understand the purpose of this study, also agree to comply with protocol and sign the informed consent form voluntarily.
Exclusion criteria
* Subject whose mRS score was greater or equal to 3 during the clinical evaluation before enrollment; * Subject with recurrent aneurysm which was already embolized through stent-assisted coiling surgery; * Subject with multiple aneurysms that cannot be treated by single stent; * Subject with aneurysm ruptured within 30 days; * Subject who is not suitable for anesthesia or endovascular surgery; * Subject with significant stenosis of the parent arterty(\>50%) * Subject who underwent major sugical procedure (such as internal fixation for limb fractures, tumor resection, surgery for vital organs, etc.) within 30 days before signing the ICF or would underwent major sugical procedure 60 days after signing the ICF; * Subject who is currently participating in a clinical trial of another drug or device which has not met the primary endpoint, or who are expexted to participate in a clinical trial of another durg or device; * Subject with conditions or pathological changes which may interfere with the use of instrument, including but not limited to: carotid artery dissection, vasculitis, aortic dissection, etc; * Subject who is contraindicated with stent-assisted coiling: Subject with allergy to required anti-platelet and/or heparin medications required for treatment; Subject with allergy to radiographic contrast; Subject with allergy to Nitinol, platinum-tungsten, platinum-iridium alloy. * Women who is pregnant or now breastfeeding; * Subject with a life expectancy less than 12 months.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adequate occlusion rate of aneurysms | Time Frame: 360±60 days | The Raymond-Roy intracranial aneurysm occlusion classification was used to assess the rate of aneurysm occlusion postoperatively or at the time of primary endpoint assessment (12 months). Occlusion rates were reported as Class I: complete occlusion; Class II: residual neck; Class III: residual aneurysm. Adequate occlusion rate includes Class I and Class II. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Retreatment rate | Time Frame: 360±30 days | Percentage of subjects who had aneurysm recurrence and underwent a secondary suergry during follow-up |
| Successful stent placement | Intraoperation | Successful stent placement was defined as the stent was successfully released at the appropriate position, and covered the aneurysm's neck completely while the parent artery remained unobstructed postoperatively. |
| Incidence od in-stent stenosis (≥50%) | Time Frame: 360±30 days | — |
| Complete occlusion rate of aneurysms | Time Frame: 360±30 days | The Raymond-Roy intracranial aneurysm occlusion classification was used to assess the rate of aneurysm occlusion postoperatively or at the time of primary endpoint assessment (12 months). Occlusion rates were reported as Class I: complete occlusion; Class II: residual neck; Class III: residual aneurysm. Complete occlusion rate includes Class I |
| Incidence of ipsilateral stroke of neurological death | Time Frame: 360±30 days | — |
| Incidence of device-related severe adverse event | Time Frame: 360±30 days | — |
| Incidence of aneurysm rupture | Time Frame: 360±30 days | — |
| Incidence of device-relared stroke or death | perioperative | — |
Countries
China
Contacts
Primary ContactHuina Lu
Outcome results
None listed